Patidegib Topical Gel, 2% + Patidegib Topical Gel, Vehicle

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Basal Cell Nevus Syndrome

Conditions

Basal Cell Nevus Syndrome

Trial Timeline

Feb 19, 2019 โ†’ Dec 28, 2020

About Patidegib Topical Gel, 2% + Patidegib Topical Gel, Vehicle

Patidegib Topical Gel, 2% + Patidegib Topical Gel, Vehicle is a phase 3 stage product being developed by Sol-Gel Technologies for Basal Cell Nevus Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03703310. Target conditions include Basal Cell Nevus Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04155190Phase 2Terminated
NCT03703310Phase 3Completed

Competing Products

20 competing products in Basal Cell Nevus Syndrome

See all competitors
ProductCompanyStageHype Score
Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split DoseVerrica PharmaceuticalsPhase 2
44
sonidegibSun PharmaceuticalPre-clinical
23
Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
85
VismodegibSun PharmaceuticalPhase 2
52
Cemiplimab Injection [Libtayo]Sun PharmaceuticalPhase 2
52
Vismodegib + SonidegibSun PharmaceuticalPre-clinical
23
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
ABBV-8E12AbbViePre-clinical
23
Pembrolizumab + VismodegibMerckPhase 1/2
41
LDE225B + VehicleNovartisPhase 2/3
65
verteporfin PDTNovartisPhase 3
77
Vehicle + LDE225 0.25% + LDE225 0.75%NovartisPhase 2
52
LDE225NovartisPhase 2
52
LDE225 + PlaceboNovartisPhase 2
52
Buparlisib + SonidegibNovartisPhase 2
52
LDE225NovartisPre-clinical
23
LDE225 0.75% + VehicleNovartisPhase 2
52
VismodegibRochePre-clinical
23
ERIVEDGERochePhase 2
52
Placebo + VismodegibRochePhase 2
52